Photo from International Journal of Gynecological Cancer/LinkedIn
May 16, 2024, 02:34
Dr. Domenica Lorusso discussed the survival analysis of the PAOLA1 trial – International Journal of Gynecological Cancer
International Journal of Gynecological Cancer shared on LinkedIn:
“New episode of Weekly Podcast
Dr. Domenica Lorusso discussed the survival analysis of the PAOLA1 trial.
Highlights
- Bev+Olaparib has reported increased PFS and OS in advanced stage III-IV, newly diagnosed, high grade serous and endometrioid HRD+ ovarian cancer in the maintenance setting.
- Exploratory analysis suggest that the advantage is particularly high in low-risk patients (stage III without residual tumor at primary surgery), where a 5-y OS more than 90% has been reported suggesting some of these patients may be cured.
- In the HRp population the combination of Olaparib+Bev did non increase PFS and OS in comparison to Bev alone.
- The toxicity profile of the combination is in line with what expected with the single drugs.”
Video attached to the post.
Source: International Journal of Gynecological Cancer/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12